<div id="readability-page-1"><p>Novavax, Inc. (NASDAQ:NVAX - Get Free Report) has received an average rating of &#34;Hold&#34; from the nine research firms that are  covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a sell recommendation, one  has issued  a hold recommendation and four have issued  a buy recommendation on  the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $11.25.</p><ul><li>Analysts Think These Stocks Could More Than Double in Value</li></ul><p>A number of research firms have commented on NVAX. Wall Street Zen downgraded shares of Novavax from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday, November 8th. B. Riley  restated a &#34;buy&#34; rating and issued a $16.00 target price (down previously from $18.00) on shares of Novavax in a research note on Monday, November 10th. Bank of America  reaffirmed an &#34;underperform&#34; rating and set a $7.00 price target (down previously from $9.00) on shares of Novavax in a research report on Wednesday, August 20th. Cantor Fitzgerald assumed coverage on Novavax in a research note on Friday, October 24th. They issued an &#34;overweight&#34; rating and a $18.00 price target for the company. Finally, JPMorgan Chase &amp; Co. lowered their price objective on Novavax from $7.00 to $6.00 and set an &#34;underweight&#34; rating for the company in a report on Tuesday, November 18th.</p><p><b>Get Our Latest Analysis on Novavax</b></p><h2>Novavax Price Performance</h2><ul><li>Is Biotech’s Bull Run Over? Examining Election Impacts</li></ul><p>Shares of NASDAQ NVAX opened at $6.78 on Tuesday. The company has a quick ratio of 2.24, a current ratio of 2.27 and a debt-to-equity ratio of 5.93. Novavax has a fifty-two week low of $5.01 and a fifty-two week high of $11.55. The business has a 50 day moving average price of $7.81 and a two-hundred day moving average price of $7.61. The firm has a market cap of $1.10 billion, a PE ratio of 3.79 and a beta of 2.31. </p><p>Novavax (NASDAQ:NVAX - Get Free Report) last released its earnings results on Thursday, November 6th. The biopharmaceutical company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($1.08) by ($0.17). The business had revenue of $70.45 million for the quarter, compared to analysts' expectations of $55.63 million. Novavax had a net margin of 32.10% and a negative return on equity of 217.02%. The business's quarterly revenue was down 16.7% compared to the same quarter last year. During the same quarter last year, the company posted ($0.76) earnings per share.  Sell-side analysts expect that  Novavax will post -1.46 earnings per share for the current fiscal year. </p><h2>Institutional Investors Weigh In On Novavax</h2><ul><li>Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?</li></ul><p>Several institutional investors and hedge funds have recently made changes to their positions in NVAX. Vanguard Personalized Indexing Management LLC lifted its holdings in shares of  Novavax by 11.0% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 12,755 shares of the biopharmaceutical company's stock valued at $111,000 after purchasing an additional 1,268 shares during the last quarter.  Legal &amp; General Group Plc raised its holdings in  Novavax by 1.0% during the 3rd quarter. Legal &amp; General Group Plc now owns 155,743 shares of the biopharmaceutical company's stock worth $1,350,000 after buying an additional 1,529 shares during the period.  The Manufacturers Life Insurance Company lifted its stake in  Novavax by 2.3% during the second quarter. The Manufacturers Life Insurance Company now owns 78,048 shares of the biopharmaceutical company's stock valued at $492,000 after buying an additional 1,718 shares in the last quarter.  SBI Securities Co. Ltd. boosted its holdings in shares of  Novavax by 5.5% in the second quarter. SBI Securities Co. Ltd. now owns 34,095 shares of the biopharmaceutical company's stock worth $215,000 after buying an additional 1,766 shares during the period.  Finally, E Fund Management Co. Ltd. boosted its holdings in shares of  Novavax by 9.0% in the second quarter. E Fund Management Co. Ltd. now owns 28,280 shares of the biopharmaceutical company's stock worth $178,000 after buying an additional 2,326 shares during the period. 53.04% of the stock is owned by institutional investors and hedge funds. </p><h2>Novavax Company Profile</h2> (Get Free Report)<p>Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.</p><h2>Read More</h2><ul><li>Five stocks we like better than Novavax</li><li>Quiet Period Expirations Explained</li><li>What Dollar Tree’s Surge and Home Depot’s Slide Say About Consumer Health</li><li>With Risk Tolerance, One Size Does Not Fit All</li><li>3 Stocks Most Likely to Split in 2026</li><li>What Are Dividend Champions? How to Invest in the Champions</li><li>ChargePoint's Comeback Story: Why This EV Stock Is Charging Up Again</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlZBWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlZBWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Novavax Right Now?</h2><p>Before you consider Novavax, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novavax wasn't on the list.</p><p>While Novavax currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

NVAX

<p>Novavax, Inc. (NASDAQ:NVAX) has received a consensus "Hold" rating from nine research firms. Analysts have mixed recommendations: four "sell," one "hold," and four "buy." The average target price is $11.25. Recent analyst actions include downgrades and target price adjustments. Novavax's stock opened at $6.78, with a market cap of $1.10 billion. Institutional investors have adjusted their positions in the company. Novavax focuses on developing vaccines using recombinant protein and nanoparticle technology.</p>

Novavax, Inc. (NASDAQ:NVAX) Receives Consensus Recommendation of "Hold" from Brokerages